Urinary metabolite markers of precocious puberty.

Qi Y, Li P, Zhang Y, Cui L, Guo Z, Xie G, Su M, Li X, Zheng X, Qiu Y, Liu Y, Zhao A, Jia W, Jia W

Molecular & cellular proteomics : MCP25 Oct 2011Cited by 78 (Europe PMC)

PMID22027199PMCIDPMC3270102DOI10.1074/mcp.m111.011072PepBankPUB-22027199

Summary

The incidence of precocious puberty (PP, the appearance of signs of pubertal development at an abnormally early age), is rapidly rising, concurrent with changes of diet, lifestyles, and social environment. The current diagnostic methods are based on a hormone (gonadotropin-releasing hormone) stimulation test, which is costly, time-consuming, and uncomfortable for patients. The lack of molecular biomarkers to support simple laboratory tests, such as a blood or urine test, has been a long standing bottleneck in the clinical diagnosis and evaluation of PP. Here we report a metabolomic study using an ultra performance liquid chromatography-quadrupole time of flight mass spectrometry and gas chromatography-time of flight mass spectrometry. Urine metabolites from 163 individuals were profiled, and the metabolic alterations were analyzed after treatment of central precocious puberty (CPP) with triptorelin depot. A panel of biomarkers selected from >70 differentially expressed urinary metabolites by receiver operating characteristic and logistic regression analysis provided excellent predictive power with high sensitivity and specificity for PP. The altered metabolic profile of the PP patients was characterized by three major perturbed metabolic pathways: catecholamine, serotonin metabolism, and tricarboxylic acid cycle, presumably resulting from activation of the sympathetic nervous system and the hypothalamic-pituitary-gonadal axis. Treatment with triptorelin depot was able to normalize these three altered pathways. Additionally, significant changes in the urine levels of 4-hydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, indoleacetic acid, 5-hydroxytryptophan, and 5-hydroxykynurenamine in the CPP group suggest that the development of CPP condition may involve an alteration in symbiotic gut microbial composition.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialMechanism
In central precocious puberty patients, triptorelin depot normalized the altered catecholamine, serotonin metabolism, and tricarboxylic acid cycle pathways.
In plain wordsIn patients with early puberty, triptorelin depot normalized three altered metabolic pathways.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableNormalization of altered metabolic pathways
Study
n: not reported in source
Outcome group
Metabolic pathways and metabolomics · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Treatment with triptorelin depot was able to normalize these three altered pathways.
2 context sentences(design, population, supporting numbers)
Summary · context
The altered metabolic profile of the PP patients was characterized by three major perturbed metabolic pathways: catecholamine, serotonin metabolism, and tricarboxylic acid cycle, presumably resulting from activation of the sympathetic nervous system and the hypothalamic-pituitary-gonadal axis.
Summary · context
Urine metabolites from 163 individuals were profiled, and the metabolic alterations were analyzed after treatment of central precocious puberty (CPP) with triptorelin depot.
Show in the study text Report a problemFND-2202719901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.